The downside was, as so often with incretins, side-effects, with 16% of patients in the high-dose group suffering so badly they withdrew from treatment. While this is not as large a proportion as seen in trials of experimental obesity therapies from Boehringer [#msg-172204950] and Altimmune [#msg-171498058], it raises the question of how much toxicity regulators and patients will tolerate.
…the discontinuations seen with the high dose of retatrutide…[were all] due to gastrointestinal issues…
…Nausea and vomiting were more of a problem with the triple G [i.e. Retatrutide] than with Wegovy and Mounjaro, and SVB analysts singled out the 7% rate of cutaneous hyperesthesia – hypersensitivity of the skin – as something requiring further investigation and management.
The efficacy at the highest dose is superb, but the therapeutic window may be relatively narrow.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.